E ect of a specific endothelin receptor A antagonist and an angiotensin- converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis

attenuated the decreases in mRNA levels for HSPG (P<0.01) in glomeruli of PAN-injected rats. Enalapril Background. We previously reported that mRNA levels for extracellular matrix (ECM) components had little e ect on increased glomerular mRNA levels for MMP-2 and TIMP-1 in PAN nephrosis, whereas and endothelin (ET)-1 are upregulated in glomeruli of puromycin aminonucleoside (PAN) nephrosis. FR139317 attenuated the increases in glomerular mRNA levels for MMP-2 (P<0.01) and TIMP-1 Angiotensin-converting enzyme (ACE) inhibitors are e ective in experimental models of renal injury, includ(P<0.01). Conclusions. These data suggest that the beneficial ing PAN nephrosis. This study was designed to assess whether the glomerular expression of mRNA for ECM e ects of enalapril and FR139317 may be related to modulation of glomerular mRNA expression of ECM components, ET-1, metalloproteinases (MMP), and a tissue inhibitor of metalloproteinases (TIMP) is moducomponents and ET-1 and that these agents may follow a di erent mechanism in regulating the glomerlated by a specific endothelin receptor A antagonist (FR139317) or angiotensin-converting enzyme ular mRNA expression for MMP-2 and TIMP-1 in PAN nephrosis. inhibitor (enalapril ) in PAN-injected rats. Methods. Animals were divided into six groups.